Just before inclusion in the study, each patient underwent ophthalmic assessment of both eyes; it included best corrected Snellen visual acuity, biomicroscopy, and applanation tonometry (baseline IOP). One hour before laser capsulotomy patients received orally either 125 mg of acetazolamide sodium (28 patients) or placebo (26 patients) in a randomised, double-masked fashion. IOPs were measured before capsulotomy, and at 1, 3, and 24 hours after capsulotomy.
Intraocular pressure (IOP) elevation is a very frequent complication of neodymium-YAG (Nd-YAG) laser posterior capsulotomy.'-'0 Although this IOP elevation, which characteristically reaches a peak within the first 3 postoperative hours, usually resolves without sequelae, it may lead to visual field loss and/or loss of central vision, particularly in eyes with pre-existing glaucomatous damage.4 [10] [11] [12] Various topical ocular hypotensive agents have been used prophylactically in an attempt to prevent the postlaser IOP rise. Pretreatment with topical 1% apraclonidine'0-5 or 0 5% levobunolol'6 proved very effective, while topical 0 5% timolol maleate'7-'9 or 4% pilocarpine'920 provided only partial protection.
We designed this prospective, randomised, double-masked study to Before capsulotomy the eyes of all patients were dilated with one drop of a mixture of 5% phenylephrine and 1% tropicamide. We used a Q-switched Nd-YAG laser (Pegasus 3002, Rodenstock) with the Nd-YAG laser beam retrofocused approximately 0 3 mm behind the helium-neon beam focused on the capsule. A single application technique was used and the burst mode was not employed. Our intention was to create a 3-4 mm diameter opening in the centre of the opacified capsule using the least amount of total laser energy.
After the capsulotomy, all eyes received one drop of 0 1% dexamethasone sodium phosphate three times daily for 3 days. No additional medical therapy was given to any patient for a period of 24 hours, unless the measured IOP was greater than 35 mm Hg. If the IOP exceeded 35 mm Hg, the patient was treated with one drop 0-5% timolol maleate twice daily and 250 mg of oral acetazolamide four times daily. The patient was then observed until the IOP decreased to below 25 mm Hg.
Numerical data were recorded as mean (SD). Statistical significance for data comparison between patient groups was analysed using analysis of variance or XI analysis; p values of less than 0-01 were considered significant.
Results
Fifty four patients entered the study. Three patients treated with placebo were removed from the study because of very high IOP (>35 mm Hg). Two other patients of the same group and one treated with acetazolamide were lost to the 24 hour follow-up examination and were not included in the 24 hour IOP measurements.
There was no statistically significant difference between the two groups of patients with regard to sex, age, IOP before prophylactic treatment, and time interval from cataract surgery to posterior capsulotomy (Table 1) . Additionally, there was no statistically significant difference between these groups of patients with regard to mean laser energy per pulse, number of pulses, or total laser energy used for capsulotomy per patient ( Table 2 ). Just before capsulotomy the mean IOP of the acetazolamide group presented a slight decrease because of the earlier use of acetazolamide.
During the first 3 hours following capsulotomy, we noticed a mean IOP elevation in the placebo group which ranged from 5 8 to 6a 1 mm Hg above baseline IOP. However, the mean IOP elevation in the acetazolamide group ranged from 0-7 to 1-1 mm Hg (p<0001) ( Table 3) . Twenty four hours following capsulotomy there was no statistically significant difference in the mean IOP elevation between the two groups of patients (Table 3) .
Within the first 3 hours following laser treatment, 16 of 26 eyes (61-5%) ofthe placebo group had an IOP elevation greater than 5 mm Hg compared with only four of 28 eyes (14-3%) of the acetazolamide group (p<0001) ( Table 4) . At the same time, eight of the 26 eyes (30 8%) of the placebo group developed an IOP rise greater than 10 mm Hg. However, none of the eyes of the acetazolamide group developed such a high IOP rise (p<0-001) ( Table 4) .
None of the eyes of the acetazolamide group Several studies'"20 have shown that the prophylactic use of other antiglaucoma medication such as apraclonidine, levobunolol, timolol, and pilocarpine is also effective in preventing or reducing the IOP rise after Nd-YAG laser capsulotomy. As some of this medication is not readily available worldwide and/or cannot be administered to certain patients because of contraindications, we believe that a widely available drug (such as oral acetazolamide), given in a very low dose, is an important alternative therapy in the prevention of vision-threatening IOP elevation in patients undergoing Nd-YAG laser posterior capsulotomy.
